Novartis today announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily, DP2 receptor antagonist fevipiprant (QAW039). The pooled analyses of the LUSTER trials did not meet3 the clinically relevant threshold for reduction in rate of moderate-to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses (150mg / 450 mg).
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to intranasal corticosteroids.
Before you start a home building or renovation project, consider how the products you use or install may impact the overall health of your home. During construction, a lot of dust is generated and volatile organic compounds (VOCs) can be released. It’s important to consider choosing materials that emit fewer gases or other asthma triggers.
Asthma can be scary and overwhelming. It is the leading chronic disease in children and the top reason for missed school days due to chronic illness. I’m sure if you’ve been touched by this disease, you might empathize with this experience from LaJoy and her daughter, Abria.
The Asthma and Allergy Foundation of America (AAFA) has released a new tool for the asthma community – an asthma health chatbot. The chatbot is available 24 hours a day, seven days a week to help people get answers to their questions about asthma or health insurance. This can be a valuable tool for people shopping for health insurance during the final 10 days left in the federal open enrollment period.
Welcome to your November advocacy update. I’m Jenna Riemenschneider, Director of Advocacy at the Asthma and Allergy Foundation of America (AAFA).
Today, the Asthma and Allergy Foundation (AAFA) met with the Department of Transportation alongside several disability advocacy groups. We discussed service animal regulations and the impact of growing numbers of emotional support animals on airlines. We shared how difficult it is to travel when you have asthma and/or pet dander allergy. We’re working together to ensure people are treated fairly when it comes to disability accommodations—and not privileging one disability type over another.
Representatives Eliot L. Engel (D-NY-16), Fred Upton (R-MI-06), Pete King (R-NY-02) and TJ Cox (D-CA-21), all members of the House Asthma and Allergy Caucus, have introduced legislation to honor Elijah E. Cummings’ long-time advocacy for those living with asthma. The Elijah E. Cummings Family Asthma Act would expand federal, state, and local efforts to improve care for individuals with asthma.
As we gear up (and bundle up) for the holiday season, people with asthma who live in cold climates may notice they are having a tougher time breathing. That’s because when you breathe in dry, cold air, your airways start to narrow, making it hard to breathe. Fortunately, there are a few things you can do to reduce asthma triggers and the chance of having asthma symptoms or an attack this winter season.
For many people, the health risks posed by indoor air quality can often be significantly higher than outdoor air. Animal dander, pollen, mold, dust mites and fumes released by cooking, burning fuel or cleaning products can all negatively impact your indoor air. One way you can improve your indoor air quality is with a CERTIFIED asthma & allergy friendly® air cleaner. Here are some things to keep in mind when shopping for an air cleaner.
Are metered dose inhalers (MDIs) contributing to climate change? British researchers estimated the impact of gases used in MDIs on air pollution. They suggest if people switched to dry powder inhalers (DPIs), it could reduce the impact on our planet. What does this mean for people with asthma?
The Asthma and Allergy Foundation of America (AAFA) has created a series of videos for teens with asthma who will be starting college or are in their first year. Each animated video is short and easy to understand.
Welcome to our first monthly advocacy update. My name is Jenna Riemenschneider, Director of Advocacy at the Asthma and Allergy Foundation of America (AAFA). I'm pictured above with Mark Vieth, Senior Vice President at Cavarocchi Ruscio Dennis Associates, at a meeting with Airlines for America. Through this monthly blog series, I will update you on our advocacy efforts. We have already had a busy fall. This first post will include our September and October activity.
We know that children with pollen food allergy syndrome (PFAS) also suffer from seasonal allergies. A new study being presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Houston shows that allergy shots (subcutaneous immunotherapy) can be effective in reducing PFAS symptoms for pediatric patients.
At some point you may have had a reaction to penicillin and were told you were allergic. And there’s a good chance it has stayed in your chart throughout your childhood and into adulthood. But 9 of 10 Americans who think they have a penicillin allergy have either outgrown it or never had it in the first place. That said, it’s important to get tested by an allergist to know if you have a true penicillin allergy so you know whether to avoid the drug.